- For Individuals and Families
- For Businesses and Employers
- For Our Clients
- For Individuals (Personal Insurance)
- For Employees (Group Insurance)
- For Our Partners
- Resource Centre
- Contact Us
National University Cancer InstituteNUH Medical Centre, Level 8 - 10. 5 Lower Kent Ridge Road. Singapore 119074 | Opening Hours: Mon – Fri: 8:30am to 5:30pm Sat: 8:30am to 12:30pm Sun & PH: Closed Tel: 6779 2778
Dr Tan Lip Kun graduated from Leicester Medical School, UK, in 1989. She obtained her MRCP in 1993 and completed her post-graduate training in Haematology in 1998 and obtained her MRCPath in 1998. She was conferred FRCPath in 2006. Dr Tan has experience in both laboratory and clinical haematology. Her main field of interests in Haematology is in Acute Leukaemias, Lymphoproliferative Diseases, Haematopoietic Stem Cell Transplantation & Cell Therapy and Transfusion Medicine..
Dr Tan was the previous Program Director of the Haematopoietic Stem Cell Transplant Program in NUH. She was instrumental in setting up the transplant service at NUH. She recently stood down from this position in January 2019. She is the Medical Director for both the Processing Facility and Collection Facility of Stem Cell Transplant Program She oversees the Stem Cell Laboratory and Tissue Engineering & Cell Therapy (TECT) Laboratory) as well as the Apheresis Unit) at the National University Cancer Institute, Singapore (NCIS).
Dr Tan is the Medical Director of the hospital’s Blood Transfusion Service. She serves as an Advisory and Member of the Hospital Blood Usage Committee. She is an appointed member of the Product Vigilance Advisory Committee of HSA. Dr Tan is an Assistant Professor with the Department of Pathology, Yong Loo Lin Medical School, NUS. She participates in both undergraduate and postgraduate teaching. She was a previous member of the Exit Examination Committee for Haematology Residency.
Dr Tan has recently been appointed by MOH as the protem Executive Director for ACTRIS (Advanced Cell Therapy and Research Institute, Singapore). ACTRIS is involved in setting up a National Cell Therapy Program as well as a designing, constructing and running a national manufacturing facility. The aim is of ACTRIS is to facilitate cell therapy work in the Singapore ecosystem.
MB ChB, FRCP, FRCPath